Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  International journal of clinical pharmacology and therapeutics

• Publication date

  2007-10-01

• Fields of study

  Agricultural and Food Sciences, Medicine

• Identifiers
  DOI 10.5414/CPP45539PMID 17966839
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

  2006cited by this paper
• IDENTIFICATION OF HUMAN LIVER CYTOCHROME P450 ENZYMES RESPONSIBLE FOR THE METABOLISM OF LONAFARNIB (SARASAR)

  2006cited by this paper
• Effects of Food on the Clinical Pharmacokinetics of Anticancer Agents

  2004cited by this paper
• Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations.

  2003cited by this paper
• Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy.

  2003cited by this paper
• Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.

  2001cited by this paper
• Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.

  2001cited by this paper
• The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.

  2001cited by this paper
• Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules*

  2000cited by this paper
• Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.

  1999cited by this paper
• Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?

  1997cited by this paper

• Challenges in Extrapolating Healthy Volunteer Pharmacokinetics to Oncology Populations: Advocating for a Holistic Perspective

  2025cites this paper
• HBV and HDV: New Treatments on the Horizon

  2021cites this paper
• Interactions- Readdressing the issue

  2021cites this paper
• Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection

  2017cites this paper
• Assessment of drug–drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer

  2017cites this paper
• Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects

  2016cites this paper
• Lonafarnib for cancer and progeria

  2012cites this paper
• Interacción de los antineoplásicos orales con los alimentos: revisión sistemática

  2009cites this paper
• [Antineoplastic oral agents and drug-nutrient interactions: a sistematic review].

  2009cites this paper